
About Us
We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,
including alopecia, acne, COVID-19, prostate cancer, liver cancer, breast cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.


Small-molecule drugs
Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics
Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers.

Combination therapies
To provide the best treatment for prostate, breast, and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.
Our Platforms
R&D Platform
We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.
Commercial Operation
In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.
News Center
Kintor Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine
Kintor Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
Kintor Pharma Announces 2023 Interim Results and Recent Business Highlights
Work at Kintor


Business
News Center
Contact Us
Find Us


Copyright: Kintor Pharmaceutical Limited retains all copyrights. 苏ICP备19028699号-2 Powered by 300.cn
Complaints and Suggestions Tel: +86 512 62639935 Email: public@kintor.com.cn